Beta-2 Adrenergic and Muscarinic Receptors — COPD/Asthma

Bronchodilation in obstructive airway disease is achieved through two complementary receptor systems: beta-2 adrenergic receptors (beta-2-AR) and muscarinic acetylcholine receptors (mAChR), both modulating airway smooth muscle tone via opposing intracellular signalling cascades. Beta-2-AR is a Gs-coupled GPCR expressed on bronchial smooth muscle, mast cells, and epithelium; agonist binding activates adenylyl cyclase, elevating cAMP and activating PKA, which phosphorylates myosin light chain kinase and promotes smooth muscle relaxation. M3 muscarinic receptors on airway smooth muscle and submucosal glands couple via Gq/G11 to phospholipase C, generating IP3 and DAG, causing smooth muscle contraction and mucus secretion — the dominant bronchoconstrictive cholinergic tone in COPD.

In COPD, increased cholinergic tone from the vagus nerve is the principal reversible component of airflow limitation, making long-acting muscarinic antagonists (LAMAs) the cornerstone of pharmacological bronchodilation. Combining a LABA and LAMA in a single inhaler achieves additive bronchodilation through complementary mechanisms without pharmacological interaction. Triple inhaler therapy (ICS/LABA/LAMA) is indicated where eosinophilic airway inflammation coexists, based on blood eosinophil count as a biomarker for ICS response. In asthma, the dominant driver of reversible obstruction is mast cell and eosinophil-mediated inflammation with bronchospasm, where ICS-containing regimens remain the treatment backbone.

Inhaler device selection, technique, and patient preference are critical determinants of effective drug delivery and real-world outcomes in both COPD and asthma. Different device types (pMDI, DPI, soft-mist inhaler) have distinct flow rate requirements, particle size distributions, and lung deposition profiles. LABA/LAMA combination devices approved in the UK include umeclidinium/vilanterol, glycopyrronium/indacaterol, and tiotropium/olodaterol, among others, with ICS/LABA/LAMA triple combinations including fluticasone furoate/umeclidinium/vilanterol and budesonide/glycopyrronium/formoterol.